Literature DB >> 2183609

Safety of parenteral third-generation cephalosporins.

F R Fekety1.   

Abstract

Knowledge of side effects associated with different cephalosporins may be of help to prescribers. There are several side effects that are common to all cephalosporins, but overall, cefotaxime and ceftizoxime cause the fewest adverse reactions. Bleeding is probably the most common serious side effect of cephalosporins. Moxalactam causes coagulopathy and bleeding more often than do other cephalosporins, probably because it is carboxylated and has a methylthiotetrazole side chain. Cefoperazone also has a methylthiotetrazole side chain and may cause bleeding, particularly when used in doses greater than 4 g per day. Ceftriaxone has a similar side chain and there is some evidence that it can induce a coagulopathy. Coagulation tests should be monitored when any of the third-generation cephalosporins are given to patients with a high risk of bleeding. Disulfiram-like reactions are also related to the side chains associated with coagulation defects and have been reported when patients receiving cefoperazone, moxalactam, or ceftriaxone have ingested alcohol. Seizures have been reported with ceftazidime, but are uncommon. Hematologic reactions are rare with all third-generation cephalosporins. Benign diarrhea and Clostridium difficile colitis probably occur most often with moxalactam, cefoperazone, ceftazidime, and ceftriaxone, but there are few good data on this issue. Ceftriaxone has the unique ability to cause sludge (also referred to as pseudolithiasis) to form in the gallbladder, particularly in children. This may be associated with nausea, anorexia, epigastric distress, and colic, and is usually detected using ultrasonography. The sludge dissolves and symptoms subside after therapy is discontinued. None of the third-generation cephalosporins is clearly significantly nephrotoxic, even when combined with aminoglycosides. Most of the third-generation cephalosporins have surprisingly few serious side effects, which make them attractive for use in the treatment of a wide variety of serious infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183609     DOI: 10.1016/0002-9343(90)90326-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  20 in total

Review 1.  Antibacterial-induced nephrotoxicity in the newborn.

Authors:  V Fanos; L Cataldi
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

2.  [Use-risk consideration of anti-infective agents from the point of view of the licensing authority].

Authors:  W Christ; B Esch
Journal:  Infection       Date:  1991       Impact factor: 3.553

3.  Vitamin K supplementation during prophylactic use of cefoperazone in urologic surgery.

Authors:  S D Rockoff; M J Blumenfrucht; R J Irwin; R H Eng
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

4.  Drug rash with eosinophilia and systemic symptoms (DRESS) probably induced by cefotaxime: a report of two cases.

Authors:  Karim Aouam; Amel Chaabane; Adnen Toumi; Nadia Ben Fredj; Foued Ben Romdhane; Naceur A Boughattas; Mohamed Chakroun
Journal:  Clin Med Res       Date:  2011-08-04

5.  Pharmacokinetics of cefovecin in cynomolgus macaques (Macaca fascicularis), olive baboons (Papio anubis), and rhesus macaques (Macaca mulatta).

Authors:  Brigitte M Raabe; Jamie Lovaglio; G Scott Grover; Scott A Brown; Joseph F Boucher; Yang Yuan; Jacqueline R Civil; Kimberly A Gillhouse; Makeida N Stubbs; Amber F Hoggatt; Lisa C Halliday; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-05       Impact factor: 1.232

Review 6.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

7.  Ceftriaxone protects against tobramycin nephrotoxicity.

Authors:  D Beauchamp; G Thériault; L Grenier; P Gourde; S Perron; Y Bergeron; L Fontaine; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Adverse effects of newer cephalosporins. An update.

Authors:  J W Thompson; R F Jacobs
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 9.  Cephalosporins--cefotaxime 10 years later, a major drug with continued use.

Authors:  H C Neu
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 10.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.